Source Themes

Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al, 2020)

Abstract: NB: The author stands by all analytical and statistical aspects of this preprint. However, subsequent to this analysis, further details of the original study have been released- with major uncertainties in study design, reporting, choice of endpoints, and most importantly, data integrity [1, 2].

Sentinel Event Surveillance to Estimate Total SARS-CoV-2 Infections, United States

Abstract: Human infections with a novel coronavirus (SARS-CoV-2) were first identified via syndromic surveillance in December of 2019 in Wuhan China. Since identification, infections (coronavirus disease-2019; COVID-19) caused by this novel pathogen have spread globally, with more than 180,000 confirmed cases as of March 16, 2020.

Study protocol for a cluster-randomized split-plot design trial to assess the effectiveness of targeted active malaria case detection among high-risk populations in Southern Lao PDR (the AcME-Lao study)

Abstract Introduction: Novel interventions are needed to accelerate malaria elimination, especially in areas where asymptomatic parasitemia is common, and where transmission generally occurs outside of village-based settings. Testing of community members linked to a person with clinical illness (reactive case detection, RACD) has not shown effectiveness in prior studies due to the limited sensitivity of current point-of-care tests.

FluSense: A Contactless Syndromic Surveillance Platform for Influenza-Like Illness in Hospital Waiting Areas

Abstract: We developed a contactless syndromic surveillance platform FluSense that aims to expand the current paradigm of influenza-like illness (ILI) surveillance by capturing crowd-level bio-clinical signals directly related to physical symptoms of ILI from hospital waiting areas in an unobtrusive and privacy-sensitive manner.